⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BDRX News
Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
globenewswire.com
BDRX
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
globenewswire.com
BDRX
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
accessnewswire.com
BDRX